These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 26922873)

  • 21. Pancreatic amylin as a centrally acting satiating hormone.
    Lutz TA
    Curr Drug Targets; 2005 Mar; 6(2):181-9. PubMed ID: 15777188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight.
    Mack CM; Soares CJ; Wilson JK; Athanacio JR; Turek VF; Trevaskis JL; Roth JD; Smith PA; Gedulin B; Jodka CM; Roland BL; Adams SH; Lwin A; Herich J; Laugero KD; Vu C; Pittner R; Paterniti JR; Hanley M; Ghosh S; Parkes DG
    Int J Obes (Lond); 2010 Feb; 34(2):385-95. PubMed ID: 19935749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amylin Acts in the Lateral Dorsal Tegmental Nucleus to Regulate Energy Balance Through Gamma-Aminobutyric Acid Signaling.
    Reiner DJ; Mietlicki-Baase EG; Olivos DR; McGrath LE; Zimmer DJ; Koch-Laskowski K; Krawczyk J; Turner CA; Noble EE; Hahn JD; Schmidt HD; Kanoski SE; Hayes MR
    Biol Psychiatry; 2017 Dec; 82(11):828-838. PubMed ID: 28237459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Role of amylin in glucose homeostasis and its perspective use in diabetes management].
    Otto-Buczkowska E; Mazur-Dworzecka U; Dworzecki T
    Przegl Lek; 2008; 65(3):135-9. PubMed ID: 18624122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Steve Woods's contribution to research on amylin's eating inhibitory effect.
    Lutz TA
    Physiol Behav; 2011 Apr; 103(1):25-30. PubMed ID: 21035478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The interaction of amylin with other hormones in the control of eating.
    Lutz TA
    Diabetes Obes Metab; 2013 Feb; 15(2):99-111. PubMed ID: 22862822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pramlintide for the treatment of diabetes mellitus.
    Kleppinger EL; Vivian EM
    Ann Pharmacother; 2003; 37(7-8):1082-9. PubMed ID: 12841822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Control of energy homeostasis by amylin.
    Lutz TA
    Cell Mol Life Sci; 2012 Jun; 69(12):1947-65. PubMed ID: 22193913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of Amylin in Type 1 and Type 2 Diabetes.
    Hieronymus L; Griffin S
    Diabetes Educ; 2015 Dec; 41(1 Suppl):47S-56S. PubMed ID: 26424675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GLP-1 and Amylin in the Treatment of Obesity.
    Jorsal T; Rungby J; Knop FK; Vilsbøll T
    Curr Diab Rep; 2016 Jan; 16(1):1. PubMed ID: 26699764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amylin: Pharmacology, Physiology, and Clinical Potential.
    Hay DL; Chen S; Lutz TA; Parkes DG; Roth JD
    Pharmacol Rev; 2015 Jul; 67(3):564-600. PubMed ID: 26071095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Link between Type 2 Diabetes and Neurodegeneration: Roles for Amyloid-β, Amylin, and Tau Proteins.
    Bharadwaj P; Wijesekara N; Liyanapathirana M; Newsholme P; Ittner L; Fraser P; Verdile G
    J Alzheimers Dis; 2017; 59(2):421-432. PubMed ID: 28269785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.
    Singh-Franco D; Robles G; Gazze D
    Clin Ther; 2007 Apr; 29(4):535-62. PubMed ID: 17617279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amylin and GLP-1 target different populations of area postrema neurons that are both modulated by nutrient stimuli.
    Züger D; Forster K; Lutz TA; Riediger T
    Physiol Behav; 2013 Mar; 112-113():61-9. PubMed ID: 23438370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose.
    Hayes MR; Mietlicki-Baase EG; Kanoski SE; De Jonghe BC
    Annu Rev Nutr; 2014; 34():237-60. PubMed ID: 24819325
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of amylin on eating and adiposity.
    Lutz TA
    Handb Exp Pharmacol; 2012; (209):231-50. PubMed ID: 22249817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models.
    Clapper JR; Athanacio J; Wittmer C; Griffin PS; D'Souza L; Parkes DG; Roth JD
    Eur J Pharmacol; 2013 Jan; 698(1-3):292-8. PubMed ID: 23178527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced amylin-mediated body weight loss in estradiol-deficient diet-induced obese rats.
    Trevaskis JL; Turek VF; Wittmer C; Griffin PS; Wilson JK; Reynolds JM; Zhao Y; Mack CM; Parkes DG; Roth JD
    Endocrinology; 2010 Dec; 151(12):5657-68. PubMed ID: 20962049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic pramlintide decreases feeding via a reduction in meal size in male rats.
    Kern KA; DiBrog AM; Kaur K; Przybysz JT; Mietlicki-Baase EG
    Peptides; 2024 Jun; 176():171197. PubMed ID: 38493922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.
    Fineman M; Weyer C; Maggs DG; Strobel S; Kolterman OG
    Horm Metab Res; 2002 Sep; 34(9):504-8. PubMed ID: 12384827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.